Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675632 | 0.89 | TRPV1 (0.61) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL3999015 | 0.86 | MEN1 (0.54) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL3999020 | 0.86 | MEN1 (0.54) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL13675829 | 0.85 | MEN1 (0.58) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL13675792 | 0.84 | NAMPT (0.48) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL3939567 | 0.83 | NPC1 (0.62) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL3939561 | 0.83 | NPC1 (0.62) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL13675754 | 0.81 | MCHR1 (0.64) | MAOBMCHR1 | |
| SCHEMBL3997657 | 0.80 | TRPV1 (0.63) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL3997649 | 0.80 | TRPV1 (0.63) | MEN1NPC1POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | MEN1 3504/4885NPC1 2982/4885POLB 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.